Search Results - "Khosrowjerdi, S."

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E.J., Ricciuti, B., Gainor, J.F., Kehl, K.L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L.M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R.M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K.C., Carter, B.W., Heymach, J.V., Altan, M., Hellmann, M.D., Awad, M.M.

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50 by Gainor, J.F., Rizvi, H., Jimenez Aguilar, E., Skoulidis, F., Yeap, B.Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Zhang, J., Roth, J.A., Grishman, J., Anderson, D., Little, B.P., Carter, B.W., Arbour, K., Sauter, J.L., Mino-Kenudson, M., Heymach, J.V., Digumarthy, S., Shaw, A.T., Awad, M.M., Hellmann, M.D.

“…Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1…”
Get full text

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E J, Ricciuti, B, Gainor, J F, Kehl, K L, Kravets, S, Dahlberg, S, Nishino, M, Sholl, L M, Adeni, A, Subegdjo, S, Khosrowjerdi, S, Peterson, R M, Digumarthy, S, Liu, C, Sauter, J, Rizvi, H, Arbour, K C, Carter, B W, Heymach, J V, Altan, M, Hellmann, M D, Awad, M M

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text